What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Another Take on the 2022 EULAR RA Treatment Guidelines
Dr. Peter Nash reviews the new 2022 EULAR RA Treatment Guidelines, presented at #EULAR2022.
Watch video →
EULAR 2022 - Day 2 Faculty Recap Panel
Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022.
Watch video →
2022 ASAS/EULAR Recommendations on the Management of Axial Spondyloarthritis
Dr. Peter Nash discusses the new ASAS/EULAR Spondyloarthritis treatment guidelines presented at EULAR 2022
Watch video →
RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
Dr. Jonathan Kay reports on RA-related sessions and abstracts from day 1 at EULAR 2022.
Watch video →
New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force.
Watch video →
EULAR 2022 - Day 1 Faculty Recap Panel
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at EULAR 2022 - Guidelines, Lupus, and more.
Watch video →
Dr. John Cush RheumNow
3 years 1 month ago
FDA Approves BA.4 and BA.5 Omicron COVID Booster Vaccines
Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022.
https://t.co/VzQBFgvAqu https://t.co/r0pQuoDVcn
Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on RheumNow.com.
While hypertension and arthritis are very common disorders, the association between them is unclear. Analysis of NHANES data suggests that both rheumatoid arthritis (RA) and osteoarthritis (OA) are strongly associated with hypertension (HTN).
The NHANES (National Health and Nutrition Examination Survey) of non-pregnant adult, aged ≥ 20 years examined data 48,372 eligible participants between 1999–2018.
Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.
Dr. John Cush RheumNow
3 years 1 month ago
Study of 497 pts referred by general practitioners to rheumatologist (2018-19) showed:
- GP Dx changed by Rheum in 58%
- Low complexity Dx (FM, OA) acct for 50% referrals
- 46% of referrals inappropriate
- GP correlations w/ Rheum Dx poor (κ < 0.5) https://t.co/q592iHQZbq https://t.co/XyPdtpHQGK
Dr. John Cush RheumNow
3 years 1 month ago
Recent review of AOSD suggests: - AOSD & SJIA are the same - Classify dz as systemic or articular - #MAS occurs in up to 23% - Yamaguchi & Fautrel criteria are widely used - Cytokines important: IL-1, IL-6, IL-18, IL-37 - only Canakinumab is FDA-approved https://t.co/4ERA56Wqcb https://t.co/FkIWxIrwxX
Dr. John Cush RheumNow
3 years 1 month ago
NICE Guidelines on Gout Diagnosis and Management
NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.
https://t.co/ckDrfVAynN https://t.co/jzBviwpxGL
The diagnosis of idiopathic inflammatory myopathies (IIMs) can be informed by the 2017 EULAR/ACR classification criteria, but their utility in patients with clinically amyopathic dermatomyositis (CADM) and anti–melanoma differentiation–associated protein 5 (anti–MDA-5)–positive IIM is less certain.
Dr. John Cush RheumNow
3 years 1 month ago
Risk of TNFi-related psoriasis in 5088 TNFi Rx children w/ IBD, JIA, or CNO. Compared to non-TNFi exposed, kids on TNFi had an increased PSO risk w/ ADA (IRR 2.70; 1.53-4.75), infliximab (2.34) or etanercept (2.21) & not incr w/ DMARD use https://t.co/MyjLfeoChq https://t.co/A3JJUA1AaM
Brown Journal of Hospital Medicine BrownJHM
3 years 1 month ago
Cranial nerves exam (unknown source) #BJHM #Neurotwitter #Medtwitter #MedEd #medstudents https://t.co/NnUx6tGERn
Eric Topol EricTopol
3 years 1 month ago
New data at today's CDC/ACIP meeting on vaccine effectiveness vs BA.5 wave hospitalizations, all adults
https://t.co/64b9g7HW1h
Less protection for both 3rd and 4th dose vaccines compared with the prior wave (BA.2, BA.2.12) https://t.co/JTichjw2I3
Dr. John Cush RheumNow
3 years 1 month ago
Calling All Rheumatology Fellows! Join the ACR Fellows-in-Training Subcommittee https://t.co/FSyMjVieAD
Dr. John Cush RheumNow
3 years 1 month ago
Gout: diagnosis and management—summary of NICE guidance https://t.co/zOdPzGtqg7 https://t.co/N7CJ23vLND
Dr. John Cush RheumNow
3 years 1 month ago
OPTION-DM study of 140 diabetic neuropathy pts Rx for 16 weeks w/ one agent (& if no response) an add-on agent. At wk 16, all 3 regimens lowered nerve pain score from 6.6 to 3.3 w/ no difference between Elavil+Lyrica, Lyrica+Elavil, o Cymbalta+Lyrica) https://t.co/rijJyq1DYL https://t.co/NwHF6xuF0j
Poster Hall